News | May 26, 2025
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
EBITDA for the period rose by 23.2% to Rs. 3,797 million
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Subscribe To Our Newsletter & Stay Updated
